Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Imlygic Market Size Forecast: How Big Could The Market Get By 2030?
The historical expansion was propelled by the scarcity of choices for unresectable melanoma, initial advancements in immunotherapy, an increase in melanoma cases, the clinical endorsement of viral oncology, and its subsequent integration within oncology centers.
Anticipated expansion during the forecast period is fueled by the broadening of cancer immunotherapy pipelines, an increase in combination oncology trials, growing investments in viral therapeutics, rising melanoma diagnosis rates, and advancements in genetic modification technologies. Concurrently, major developments predicted for this period include the growth of oncolytic viral therapies, a surge in interest in immuno-oncology, the expansion of injectable cancer therapies, a focus on localized tumor treatment, and an increase in combination therapy approaches.
Get A Free Sample Report With In-Depth Market Insights:
Imlygic Market Demand Drivers Opening New Revenue Streams
The growing occurrence of melanoma is anticipated to fuel the expansion of the imlygic market in the future. Melanoma, a form of skin cancer, develops in melanocytes, the cells responsible for skin pigment production. Its incidence is on the rise due to factors like extended sun exposure, use of tanning beds, and genetic predispositions. Imlygic (talimogene laherparepvec) is an oncolytic viral therapy administered directly into melanoma tumors, designed to induce localized tumor destruction and stimulate a systemic anti-tumor immune response. For example, the National Library of Medicine, a US-based biomedical library, reported in December 2023 that melanoma cases in the EU-27 (27 member countries of the European Union) totaled 101,510 in 2022, with projections indicating an increase to 115,540 by 2040. Consequently, the rising incidence of melanoma is a key driver for the growth of the imlygic market. The worldwide expansion of healthcare infrastructure is expected to propel the growth of the imlygic market moving forward. Healthcare infrastructure encompasses the physical and organizational frameworks, facilities, resources, and systems vital for delivering health services to a population. This global expansion is driven by an aging global population, an increase in chronic diseases, and technological advancements. The efficacy and reach of imlygic depend on robust healthcare infrastructure to support its specialized storage, administration, and coordinated delivery as an oncolytic therapy. For instance, statistics released by Cross River Therapy, a US-based provider of ABA therapy services, in September 2024 indicated that the U.S. pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medicine in 2021, and projected spending is expected to increase to $605-$635 billion by 2025. Therefore, the global expansion of healthcare infrastructure is driving the growth of the imlygic market.
Imlygic Market Segment Performance And Emerging Opportunities
The imlygic market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients
2) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies
3) By Application: Melanoma Treatment, Combination Therapy, Other Cancer Types
Imlygic Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the imlygic market are Amgen Inc.
View The Full Imlygic Market Report:
Imlygic Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the imlygic market in 2025. The regions covered in the imlygic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
